已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

医学 彭布罗利珠单抗 卡培他滨 肿瘤科 艾瑞布林 内科学 乳腺癌 长春瑞滨 三阴性乳腺癌 转移性乳腺癌 紫杉烷 吉西他滨 临床终点 化疗 临床试验 蒽环类 癌症 免疫疗法 结直肠癌 顺铂
作者
Eric P. Winer,Oleg Lipatov,Seock‐Ah Im,Anthony Gonçalvès,Eva Muñoz‐Couselo,Keun Seok Lee,Peter Schmid,Kenji Tamura,Laura Testa,Isabell Witzel,Shoichiro Ohtani,Nicholas C. Turner,Stefania Zambelli,Nadia Harbeck,Fabrice André,Rebecca Dent,Xuan Zhou,Vassiliki Karantza,Jaime Mejia,Javier Cortés
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (4): 499-511 被引量:497
标识
DOI:10.1016/s1470-2045(20)30754-3
摘要

Background Pembrolizumab showed durable antitumour activity and manageable safety in metastatic triple-negative breast cancer in the single-arm KEYNOTE-012 and KEYNOTE-086 trials. In this study, we compared pembrolizumab with chemotherapy for second-line or third-line treatment of patients with metastatic triple-negative breast cancer. Methods KEYNOTE-119 was a randomised, open-label, phase 3 trial done at 150 medical centres (academic medical centres, community cancer centres, and community hospitals) in 31 countries. Patients aged 18 years or older, with centrally confirmed metastatic triple-negative breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, who had received one or two previous systemic treatments for metastatic disease, had progression on their most recent therapy, and had previous treatment with an anthracycline or taxane were eligible. Patients were randomly assigned (1:1) using a block method (block size of four) and an interactive voice-response system with integrated web-response to receive intravenous pembrolizumab 200 mg once every 3 weeks for 35 cycles (pembrolizumab group), or to single-drug chemotherapy per investigator's choice of capecitabine, eribulin, gemcitabine, or vinorelbine (60% enrolment cap for each; chemotherapy group). Randomisation was stratified by PD-L1 tumour status (positive [combined positive score (CPS) ≥1] vs negative [CPS <1]) and history of previous neoadjuvant or adjuvant treatment versus de-novo metastatic disease at initial diagnosis. Primary endpoints were overall survival in participants with a PD-L1 combined positive score (CPS) of 10 or more, those with a CPS of 1 or more, and all participants; superiority of pembrolizumab versus chemotherapy was tested in all participants only if shown in those with a CPS of one or more. The primary endpoint was analysed in the intention-to-treat population; safety was analysed in the all-subjects-as-treated population. This Article describes the final analysis of the trial, which is now completed. This trial is registered with ClinicalTrials.gov, number NCT02555657. Findings From Nov 25, 2015, to April 11, 2017, 1098 participants were assessed for eligibility and 622 (57%) were randomly assigned to receive either pembrolizumab (312 [50%]) or chemotherapy (310 [50%]). Median study follow-up was 31·4 months (IQR 27·8–34·4) for the pembrolizumab group and 31·5 months (27·8–34·6) for the chemotherapy group. Median overall survival in patients with a PD-L1 CPS of 10 or more was 12·7 months (95% CI 9·9–16·3) for the pembrolizumab group and 11·6 months (8·3–13·7) for the chemotherapy group (hazard ratio [HR] 0·78 [95% CI 0·57–1·06]; log-rank p=0·057). In participants with a CPS of 1 or more, median overall survival was 10·7 months (9·3–12·5) for the pembrolizumab group and 10·2 months (7·9–12·6) for the chemotherapy group (HR 0·86 [95% CI 0·69–1·06]; log-rank p=0·073). In the overall population, median overall survival was 9·9 months (95% CI 8·3–11·4) for the pembrolizumab group and 10·8 months (9·1–12·6) for the chemotherapy group (HR 0·97 [95% CI 0·82–1·15]). The most common grade 3–4 treatment-related adverse events were anaemia (three [1%] patients in the pembrolizumab group vs ten [3%] in the chemotherapy group), decreased white blood cells (one [<1%] vs 14 [5%]), decreased neutrophil count (one [<1%] vs 29 [10%]), and neutropenia (0 vs 39 [13%]). 61 (20%) patients in the pembrolizumab group and 58 (20%) patients in the chemotherapy group had serious adverse events. Three (<1%) of 601 participants had treatment-related adverse events that led to death (one [<1%] in the pembrolizumab group due to circulatory collapse; two [1%] in the chemotherapy group, one [<1%] due to pancytopenia and sepsis and one [<1%] haemothorax). Interpretation Pembrolizumab did not significantly improve overall survival in patients with previously treated metastatic triple-negative breast cancer versus chemotherapy. These findings might inform future research of pembrolizumab monotherapy for selected subpopulations of patients, specifically those with PD-L1-enriched tumours, and inform a combinatorial approach for the treatment of patients with metastatic triple-negative breast cancer. Funding Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鱼大智发布了新的文献求助10
刚刚
琳666发布了新的文献求助10
刚刚
白开水完成签到 ,获得积分10
1秒前
2秒前
科目三的应助被激动的忆翠采纳,获得10
2秒前
yy32323完成签到,获得积分10
4秒前
orixero的应助被xue采纳,获得10
5秒前
鳗鱼鞋垫发布了新的文献求助10
5秒前
DXB发布了新的文献求助30
5秒前
琳666完成签到,获得积分10
10秒前
JamesPei的应助被jill采纳,获得10
10秒前
10秒前
绾绾完成签到 ,获得积分10
11秒前
风呼呼的好完成签到 ,获得积分10
14秒前
xiaoxiaozi发布了新的文献求助10
15秒前
YQP完成签到 ,获得积分10
15秒前
16秒前
8R60d8的应助被冷静新烟采纳,获得10
17秒前
zbjm881完成签到,获得积分20
17秒前
66发布了新的文献求助30
17秒前
Evan完成签到,获得积分10
17秒前
WilliamTT发布了新的文献求助10
17秒前
懒羊羊完成签到 ,获得积分10
18秒前
科研通AI6.4的应助被赵师傅采纳,获得10
18秒前
JamesPei的应助被yr采纳,获得10
21秒前
22秒前
淡淡听枫完成签到,获得积分10
22秒前
22秒前
岚岚伍发布了新的文献求助10
23秒前
可爱的函函的应助被成太采纳,获得10
24秒前
晚晚完成签到 ,获得积分10
25秒前
cun完成签到,获得积分10
29秒前
李健的应助被xiaoxiaozi采纳,获得10
30秒前
铅笔完成签到,获得积分10
30秒前
32秒前
33秒前
cj关注了科研通微信公众号
34秒前
脑洞疼的应助被rocsoar采纳,获得10
35秒前
35秒前
尼丸青青关注了科研通微信公众号
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194542
求助须知:如何正确求助?哪些是违规求助? 9580381
关于积分的说明 21870692
捐赠科研通 7794154
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2560995
邀请新用户注册赠送积分活动 2484393